AI Article Synopsis

  • The study investigated death rates and predictors among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea from 2011 to 2017.
  • Among 7,226 cases, 699 (9.7%) died within an average of 167 days of starting treatment, with significant differences in timing between TB-related and non-TB-related deaths.
  • Key factors associated with higher mortality included older age, male sex, existing health conditions, low income, and specific TB characteristics, indicating high-risk groups that need targeted intervention to reduce mortality rates.

Article Abstract

Background/aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.

Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.

Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51-358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32-366 d), which was significantly earlier than the median of 184 days (IQR 68-356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75-213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.

Conclusion: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236803PMC
http://dx.doi.org/10.3904/kjim.2024.029DOI Listing

Publication Analysis

Top Keywords

days iqr
12
timing predictors
8
predictors death
8
death treatment
8
treatment patients
8
patients multidrug/rifampin-resistant
8
multidrug/rifampin-resistant tuberculosis
8
mdr/rr-tb cases
8
treatment
6
days
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!